19 / 3 / 2013 Midnight
Dean Royles, chief executive of the NHS Employers organisation, responds to the NHS Commissioning Board's agreement to extend funding for the New Medicine Service (NMS) for six months.
Mr Royles said:
"The NMS is all about reaching out into the community and working with patients at the point where they get prescriptions, to help manage their health conditions effectively. This is exactly the sort of innovation we need to see in modern healthcare.
"The NHS Employers organisation developed the NMS with the Pharmaceutical Services Negotiating Committee and continues to support its development and progress. Anecdotal feedback has been very positive and we look forward to seeing results from the evaluation of the NMS later this year."
The NHS Commissioning Board's agreement was announced today by the Pharmaceutical Services Negotiating Committee (PSNC).
The NMS was introduced from 1 October 2011. It is targeted at people with the following conditions:
- asthma and chronic obstructive pulmonary disease (COPD)
- type 2 diabetes
- antiplatelet/anticoagulant therapy
The service provides support to people who are newly prescribed a medicine to manage a long-term condition, which will generally help them to appropriately improve their medication adherence. The underlying purpose of the NMS is to promote the health and well-being of patients who are prescribed new medicines for long-term conditions in order to:
- help reduce symptoms and long term complications of the long-term condition
- identify problems with the management of the condition and the need for further information or support.